ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Polymyalgia Rheumatica (PMR)"

  • Abstract Number: 0719 • ACR Convergence 2023

    Polymyalgia Rheumatica Following SarsCOV-2 Vaccination: A Single Center Cohort Study

    Lindsay Lally1, Aliza Bloostein1, Deanna Jannat-Khan1 and Robert Spiera2, 1Hospital for Special Surgery, New York, NY, 2Hosptial for Special Surgery, New York, NY

    Background/Purpose: Polymyalgia rheumatica (PMR) incidence peaks in individuals between 70 and 80 years of age; this same group is also at increased risk of complications…
  • Abstract Number: 2393 • ACR Convergence 2023

    CXCL9/IL-6 and MMP3/CD141 Ratio Allow to Discriminate Between Isolated PMR and GCA/PMR Overlap

    andre ramon1, helene Greigert2, adrien guilloteau3, claudie cladière4, marion ciudad5, Sylvain Audia6, paul ornetti7, jean-Francis Maillefert7, Bernard Bonnotte2 and Maxime Samson2, 1Department of Rheumatology, Dijon University Hospital, Dijon, France, 2Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, 3Methodological Support Unit (USMR), Dijon-Bourgogne University Hospital, Dijon, France, 4INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Bourgogne Franche-Comté University, Dijon, France, 5INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Dijon, France, 6Department of Internal Medicine and Clinical Immunology, Dijon-Bourgogne University Hospital, Dijon, France, 7Department of Rheumatology , Dijon-Bourgogne University Hospital, Dijon, France

    Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are frequently overlapping conditions. It is estimated that 16 to 21% of PMR patients have GCA.…
  • Abstract Number: 0720 • ACR Convergence 2023

    Cognitive Function and Its Associated Factors in Polymyalgia Rheumatica

    Patricia Harkins1, Sharon Cowley2, David Kane3 and Richard Conway4, 1St James's Hospital, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Dublin, Ireland, 3Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland, 4Trinity College Dublin, Dublin, Ireland

    Background/Purpose: Over the past decade our understanding of the prevalence, and indeed impact of cognitive impairment in rheumatic diseases has increased. Intact cognitive function is…
  • Abstract Number: 2395 • ACR Convergence 2023

    Recommendations for Early Referral of Patients with Suspected Polymyalgia Rheumatica: An Initiative from the International Giant Cell Arteritis and Polymyalgia Rheumatica Study Group

    Kresten Keller1, Chetan Mukhtyar2, Andreas Wiggers Nielsen3, Andrea Hemmig4, Sarah Mackie5, Sebastian Sattui6, Ellen Margrethe Hauge3, Anisha Dua7, Toby Helliwell8, Lorna Neil9, Daniel Blockmans10, Valerie Devauchelle11, eric Hayes3, Annett Jansen Venneboer12, Sara Monti13, Cristina Ponte14, Eugenio De Miguel15, Mark Matza16, Kenneth Warrington17, Kevin Byram18, Kinanah Yaseen19, Christine Peoples20, Mike Putman21, Lindsay Lally22, Michael Finikiotis20, Simone Appenzeller23, Ugo Carmori23, CARLOS ENRIQUE TORO GUTIERREZ24, Elisabeth Backhouse25, Maria Camila Guerrero26, Victor Pimentel-Quiroz27, Helen Keen25, Claire Owen28, Thomas Daikeler29, Annette De Thurah3, Wolfgang Schmidt30, Elisabeth Brouwer12 and Christian Dejaco31, 1Department of Rheumatology, Aarhus University Hospital; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, 2Vasculitis service, Rheumatology department, Norfolk and Norwich University Hospital, Norwich, United Kingdom, 3Aarhus University Hospital, Aarhus, Denmark, 4University of Basel, Basel, Switzerland, 5Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 6University of Pittsburgh, Pittsburgh, PA, 7Northwestern University, Chicago, IL, 8Keele University, Keele, United Kingdom, 9Polymyalgia Rheumatica and Giant Cell Arteritis Scotland, Perth, United Kingdom, 10Department of General Internal Medicine, University Hospitals Leuven, Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium, 11UBO, Brest, France, 12University Medical Center Groningen, Groningen, Netherlands, 13Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, 14Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, 15Hospital Universitario La Paz, Madrid, Spain, 16Massachusetts General Hospital, Newton, MA, 17Mayo Clinic, Rochester, MN, 18Vanderbilt University Medical Center, Nashville, TN, 19Cleveland Clinic, Cleveland, OH, 20University of Pittsburgh Medical Center, Pittsburgh, PA, 21Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, 22Hospital for Special Surgery, New York, NY, 23UNICAMP, Campinas, Brazil, 24Centro de Estudios de Reumatología y Dermatología SAS, Cali, Colombia, 25University of Western Australia, Daglish, Australia, 26General practice, Cali, Colombia, 27Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, 28Austin Health, Malvern East, Australia, 29Clinic for Rheumatology, University Hospital Basel, Basel, Switzerland, 30Rheumatology, Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany, 31Azienda Sanitaria Alto Adige, Brunico, Italy

    Background/Purpose: Existing EULAR/ACR guidelines on polymyalgia rheumatica (PMR) are focused on the management by rheumatologists. However, there is no consensus regarding early referral and evaluation…
  • Abstract Number: 0721 • ACR Convergence 2023

    Characterization of Numeric Rating Scales for Symptom Assessment in Polymyalgia Rheumatica

    Tonya K Marmon1, Jason C Cole2, Claire Owen3, Sarah Mackie4 and David Katz5, 1Marmon Biostatistics, Seattle, WA, 2P3 Research Consulting, Torrance, CA, 3Austin Health, Malvern East, Australia, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 5Sparrow Pharmaceuticals, Portland, OR

    Background/Purpose: Pain, stiffness, and fatigue have been defined as core assessment domains in polymyalgia rheumatica (PMR) by the OMERACT PMR Working Group (PMRWG). Patient partners…
  • Abstract Number: 2404 • ACR Convergence 2023

    Subclinical Giant Cell Arteritis in Polimialgia Rheumatica: A Biomarker of High Relapse Risk

    Eugenio De Miguel1, Rositsa Karalilova2, PIERLUIGI MACCHIONI3, Cristina Ponte4, Edoardo Conticini5, Alessandro Tomelleri6, Sara Monti7, Irene Monjo1, Zguro Batalov2, Giulia Klinowski8, Paolo Falsetti9, David Kane10, Corrado Campochiaro11 and Alojzija Hocevar12, 1Hospital Universitario La Paz, Madrid, Spain, 2Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, 3Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, 4Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, 5Tallaght University Hospital, Dublin, Ireland, 6Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, 7Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, 8IRCCS-S.Maria Nuova, Reggio Emilia, Italy, 9San Raffaele Scientific Institute, Siena, Italy, 10Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland, 11IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, 12Department of Rheumatology, Universitiy Medical Centre Ljubljana, Ljubljana, Slovenia

    Background/Purpose: Around 20% of polymyalgia rheumatica (PMR) patients without clinical symptoms of giant cell arteritis (GCA) have subclinical GCA by image or byopsy1. However, there…
  • Abstract Number: 0747 • ACR Convergence 2023

    Clinical Phenotype of Patients with Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica

    Sharon Cowley1, Colm Kirby2, Patricia Harkins3, Richard Conway4 and David Kane5, 1Tallaght University Hospital, Dublin, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Ireland, 3St James's Hospital, Dublin, Ireland, 4Trinity College Dublin, Dublin, Ireland, 5Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland

    Background/Purpose: It has been reported that more than a quarter of patients with polymyalgia rheumatica (PMR) have subclinical giant cell arteritis (GCA). It remains unclear…
  • Abstract Number: 2516 • ACR Convergence 2023

    The Effect of Starting Prednisone Dose on the Treatment of Polymyalgia Rheumatica

    Katrina Nguyen1, Jennifer Du1, Jiaxiao shi2 and Antony Lin1, 1Kaiser SCAL, Fontana, CA, 2SCPMG, Pasadena, CA

    Background/Purpose: Polymyalgia rheumatica (PMR) is a systemic inflammatory syndrome that is characterized by widespread pain and stiffness around the shoulders, pelvic girdle and neck. PMR…
  • Abstract Number: 1036 • ACR Convergence 2023

    The Prevalence of Shoulder and Hip Joints Ultrasound Findings in Polymyalgia Rheumatica: A Multicenter International Study

    Alojzija Hocevar1, PIERLUIGI MACCHIONI2, Irene Monjo3, Rositsa Karalilova4, Edoardo Conticini5, Alessandro Tomelleri6, Cristina Ponte7, Sara Monti8, Giulia Klinowski9, Zguro Batalov4, Paolo Falsetti10, Corrado Campochiaro11 and Eugenio De Miguel3, 1Department of Rheumatology, Universitiy Medical Centre Ljubljana, Ljubljana, Slovenia, 2Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, 3Hospital Universitario La Paz, Madrid, Spain, 4Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, 5Tallaght University Hospital, Dublin, Ireland, 6Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, 7Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, 8Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, 9IRCCS-S.Maria Nuova, Reggio Emilia, Italy, 10San Raffaele Scientific Institute, Siena, Italy, 11IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy

    Background/Purpose: Musculoskeletal ultrasound (US) is a validated method for the objective assessment of the pathological changes occurring in PMR. It assists the diagnosis of the…
  • Abstract Number: 1054 • ACR Convergence 2023

    Immune Checkpoint Inhibitor Induced Polymyalgia Rheumatica Demonstrates a Similar Scintigraphic Appearance to Classical Polymyalgia Rheumatica on 18F-Fluorodeoxyglucose PET/CT

    David Liew1, Aurora Poon1, Christopher McMaster2, Russell Buchanan1, Victor Yang1, Andrew Scott1 and Claire Owen3, 1Austin Health, Heidelberg, Australia, 2Austin Health, Pascoe Vale South, Australia, 3Austin Health, Malvern East, Australia

    Background/Purpose: Of the rheumatic immune-related adverse events that follow immune checkpoint inhibitor (ICI) cancer immunotherapy, de novo PMR-like episodes without inflammatory arthritis (ICI-PMR) appear to…
  • Abstract Number: 1098 • ACR Convergence 2023

    Improving Osteoporosis Screening in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis

    Kelly Tran1, Ellen Ann Sockman1, Rachel Salyer1, Megan Young1, Aisha Abbasi1 and Devanshu Verma2, 1West Virginia University Hospital, Morgantown, WV, 2West Virginia University, Morgantown, WV

    Background/Purpose: Osteoporosis is a medical condition associated with decreased bone mass and bone architecture, which increases incidence of fragility fractures(4). It is associated with 1.5…
  • Abstract Number: 1133 • ACR Convergence 2023

    Exploring the Clinical Characteristics and Correlation with Corticosteroid Dependence in Polymyalgia Rheumatica (PMR) Patients: Insights from an Academic Center

    William Rigby1, Todd Mackenzie2, Emily Campbell1, Joshua Skydel3, Bryan Savage1, Monica Dimambro2 and Vivekanand Tiwari1, 1Dartmouth Hitchcock Medical Center, Lebanon, NH, 2Dartmouth College, Hanover, NH, 3Dartmouth-Hitchcock Medical Center, Lebanon, NH

    Background/Purpose: Polymyalgia rheumatica (PMR) treatment is primarily based on long-term corticosteroids, which results in significant toxicities. Studies1,2 have shown that patients with PMR are exposed…
  • Abstract Number: 1201 • ACR Convergence 2023

    Frailty and Its Impact on Patient Reported Outcomes in Polymyalgia Rheumatica

    Patricia Harkins1, Sharon Cowley2, David Kane3 and Richard Conway4, 1St James's Hospital, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Dublin, Ireland, 3Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland, 4Trinity College Dublin, Dublin, Ireland

    Background/Purpose: Frailty is an increasingly important construct in the field of rheumatology, aiding the identification of individuals with increased vulnerability to accelerated clinical decline and…
  • Abstract Number: 1676 • ACR Convergence 2022

    Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)

    Robert Spiera1, Sebastian Unizony2, Kenneth J. Warrington3, Jennifer Sloane Lazar4, Angeliki Giannelou5, Michael C Nivens6, Bolanle Akinlade5, Wanling Wong4, Yong Lin4, Frank Buttgereit7, Valerie Devauchelle8, Andrea Rubbert-Roth9 and Bhaskar Dasgupta10, 1Hospital for Special Surgery, New York, NY, 2Massachusetts General Hospital, Winchester, MA, 3Mayo Clinic, ROCHESTER, MN, 4Sanofi, Bridgewater, NJ, 5Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 6Regeneron Pharmaceuticals, Inc., Tarrytown, NY, NY, 7Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany, 8Université de Bretagne Occidentale, Brest, France, 9Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland, 10Anglia Ruskin University, East Anglia, United Kingdom

    Background/Purpose: IL-6 is elevated in patients with active PMR and is associated with disease activity, relapse and severity. Clinical trials with IL-6 receptor (IL-6R) inhibitors…
  • Abstract Number: 1835 • ACR Convergence 2022

    Clinical Features of Patients with Sarcoidosis and Concomitant Connective Tissue Disease

    Magdalena Harasimowicz1, Emily GIlbert2, Sarah Yi3 and Rochella Ostrowski4, 1Loyola University Medical Center Department of Internal Medicine, Chicago, IL, 2Loyola University Medical Center Division of Pulmonary and Critical Care Medicine, Maywood, IL, 3Loyola University Stritch School of Medicine, Maywood, IL, 4Loyola University Medical Center Division of Rheumatology, Maywood, IL

    Background/Purpose: Sarcoidosis is a multiorgan granulomatous disease with a prevalence of 60 per 100,000 in the United States.1 Given the low prevalence of both sarcoidosis…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology